Streptococcus uberis

Streptococcus uberis: A Comprehensive Reference

Overview and Framing

Streptococcus uberis is a bacterium whose identity in the context of dietary supplements and "natural ingredients" requires careful framing at the outset. The organism is overwhelmingly studied as a veterinary pathogen — specifically as the dominant cause of bovine mastitis in many countries — and the peer-reviewed literature reflects this primary context. A specific, taxonomically distinct strain of the species, designated S. uberis KJ2sm (also called KJ2), has been investigated in humans as a component of an oral probiotic formulation (ProBiora3®). These two contexts — the pathogenic bovine organism and the oral probiotic strain — involve the same species designation but are studied in entirely different frameworks. This article presents evidence from both contexts with explicit separation, drawing exclusively on peer-reviewed research and institutional sources.

Identity and Classification

Taxonomic Position and Nomenclature

Streptococcus uberis is a Gram-positive bacterium belonging to the family Streptococcaceae, a diverse family of bacteria that encompasses species capable of commensal and/or pathogenic traits. Phylogenetic analysis places S. uberis within the pyogenic cluster, a large grouping containing the human pathogens Streptococcus pyogenes and Streptococcus dysgalactiae.

Streptococcus uberis is characterized microscopically as a non-motile, Gram-positive coccus, appearing in pairs or chains. It is a facultative anaerobe, able to survive with or without oxygen, and typically produces small, translucent colonies when grown in a laboratory setting. This organism is categorized as an environmental pathogen because its natural habitat, or reservoir, is largely outside the animal host.

The species was historically classified in two types (Type I and Type II). Both types, formerly classified as S. uberis types I and II, are well known as causative agents of bovine mastitis. According to biochemical and serological characteristics, the two types are almost indistinguishable. The former "Type II" was subsequently reclassified as the separate species Streptococcus parauberis. The only phenotypic criterion that differentiates between Sc. uberis and Sc. parauberis is the ability of the former to produce β-d-glucuronidase.

Natural Sources and Environmental Reservoirs

Streptococcus uberis is found in the lips and skin of cows, udder tissue, and milk. It is the main cause of mastitis in some countries, especially during the winter.

S. uberis, a Gram-positive bacterial pathogen responsible for a significant proportion of bovine mastitis in commercial dairy herds, colonises multiple body sites of the cow including the gut, genital tract and mammary gland. Beyond the animal host itself, the organism is also found widely in the surrounding agricultural environment. S. uberis was detected in 63% of environmental samples, including water, soil, plant matter, bedding material, flies, and hay, in 23% of fecal samples, and in 4% of milk samples in one ribotyping study.

S. uberis proliferates well outside of the host, implying that the environment serves as the major reservoir, and it appears that proliferation is highest in straw and hay compared with sawdust or shavings as bedding sources. Levels found on heavily used pastures can reach similar numbers to other types of bedding within confinement housing. However, survival of S. uberis in the environment is limited. A report from New Zealand showed that the organism survived in the environment for less than 4 weeks. This implies that persistence in pasture is dependent on constant reintroduction, probably via faecal contamination.

Identification Methods

Identification of Str. uberis is usually based on morphological characteristics, biochemical tests, and enzyme activities. Currently, molecular tools, such as PCR-based protocols, have been developed for an accurate identification of Str. uberis isolates. Advanced proteomic approaches are also employed. The bacterium rarely has been associated with human infections. Conventional phenotypic methods can be inadequate for the identification of S. uberis; in microbiology laboratories, S. uberis is easily confused with other streptococcal species. In human clinical settings, the gold standard is confirmation by MALDI-TOF mass spectrometry or 16S rRNA gene sequencing. 16S, 23S ribosomal RNA and 16S-23S intergenic spacer gene regions are amplified with specific primers, and partial DNA sequence analysis of 16S rRNA PCR products can confirm the organism as S. uberis.

Genomic Characteristics

Comparative analysis of the complete genome sequence of S. uberis strain 0140J has been undertaken to elucidate the biology of this pathogen. The genome revealed 1,825 predicted coding sequences (CDSs) of which 62 were identified as pseudogenes or gene fragments. Comparisons with related pyogenic streptococci identified a conserved core of approximately 40% of orthologous CDSs. S. uberis utilises nutritional flexibility derived from a diversity of metabolic options to successfully occupy a discrete ecological niche. The features observed in S. uberis are strongly suggestive of an opportunistic pathogen adapted to challenging and changing environmental parameters.

Traditional and Historical Use

Streptococcus uberis, as a defined bacterial species, has no documented history of deliberate therapeutic use in human traditional medicine. Unlike plant-derived or fungal remedies, individual bacterial species at the taxonomic level of S. uberis were not recognized as distinct entities prior to the development of modern microbiology in the 19th and 20th centuries; traditional medicine systems worked with fermented foods, milks, and preparations without knowledge of constituent species.

Within agricultural and food contexts, S. uberis is a lactic acid bacterium traditionally recognized for its role in dairy fermentation and, more recently, explored as a potential ingredient in nutritional products. However, no primary ethnobotanical, ethnopharmacological, or traditional medicine monograph documents the use of S. uberis as a named ingredient in any historical medical tradition. Claims of historical therapeutic use of this specific organism in human populations are not supported by verifiable primary sources and should be treated with skepticism.

The organism has been studied primarily within the context of animal health and veterinary science. Historically, S. uberis has been studied primarily within the context of animal health, particularly bovine mastitis. Its emergence as a named ingredient in certain supplement formulations — specifically an oral probiotic context — is a development of the late 20th and early 21st centuries, grounded in laboratory isolation from the human oral cavity rather than in any ethnomedical tradition.

Key Constituents and Active Compounds

Virulence Factors (Pathogenic Context)

The biochemical constituents of S. uberis that have been most extensively characterized are its virulence factors, studied in the context of bovine mastitis pathogenesis. Despite the increasing prevalence and significant economic losses associated with S. uberis mastitis, the virulence factors behind bacterial colonization and pathogenicity have not yet been fully understood. Over the past three decades, several virulence factors of S. uberis have been described, including plasminogen activator A (PauA), acid capsule, hyaluronidase, S. uberis adhesion molecule (SUAM), glyceraldehyde-3-phosphate dehydrogenase C (GapC), Opp proteins, elongation factor Ts, hemolysin-like protein, sortase A (SrtA), surface lipoprotein, fibronectin-binding protein, C5a peptidase, lactoferrin-binding protein, and collagen-like surface-anchored protein.

Potential virulence factors produced by S. uberis and released extracellularly include hyaluronic acid capsule, hyaluronidase and uberis factor. These constituents are relevant to its pathogenic activity in cattle and have been investigated as potential targets for vaccine development, not as therapeutically beneficial compounds for human use.

Among the categories of virulence factors identified in genomic studies are adherence proteins, enzymes, immune evasion factors, manganese uptake systems, proteases, cell surface components, and serum resistance determinants.

Surface-Anchored Serine Protease (SUB1154)

Intramammary challenge studies demonstrated that virulence was dependent on the presence and correct location of a surface-anchored serine protease designated SUB1154. Unlike the wild-type strain, mutants lacking SUB1154 failed to elicit IL-1β from bovine mammary macrophages. Production of IL-1β was ablated in the presence of various inhibitors, indicating dependency on internalisation and activation of NLRP3 and caspase-1, consistent with inflammasome activation.

Hydrogen Peroxide Production (Probiotic Strain KJ2sm)

In the specific context of S. uberis strain KJ2sm used as an oral probiotic, the key biochemically active property identified in the scientific literature is the production of hydrogen peroxide. S. uberis strain KJ2 was shown to have inhibitory effects on the growth of oral pathogens implicated in periodontitis including Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis. The production of hydrogen peroxide by S. oralis KJ3 and S. uberis KJ2 was found to be the mechanism of action for pathogen growth inhibition.

S. oralis KJ3 and S. uberis KJ2 crowd out harmful bacteria by competing for the same nutrients and surface space, thus creating a healthy balance of microflora. Additionally, the low level of hydrogen peroxide produced by S. oralis KJ3 and S. uberis KJ2 provides a whitening effect on the tooth enamel.

Mechanisms of Pathogenesis

Adherence to and internalization into mammary epithelial cells are central mechanisms in the pathogenesis of S. uberis mastitis. Through these pathogenic strategies, S. uberis reaches an intracellular environment where humoral host defenses and antimicrobials in milk are essentially ineffective.

Involvement of intact microfilaments and de novo eukaryotic protein synthesis are required for bacterial invasion of mammary epithelial cells, a process that appears to occur by a receptor-mediated endocytosis mechanism. De novo bacterial protein synthesis was also required for invasion. Furthermore, S. uberis survived within mammary epithelial cells for extended periods of time without losing viability or damaging the eukaryotic cell.

Bacterial surface proteins are able to bind to extracellular matrix protein components such as fibronectin, collagen and laminin, as well as proteins in milk. These proteins play a role in adhesion to host cells and have been denominated microbial surface components recognizing adhesive matrix molecules (MSCRAMMs). This pathogen produces biofilm, and this virulence attribute has been linked to persistent infections and development of antibiotic resistance.

One notable species-level distinction relevant to zoonotic risk assessment: the S. uberis plasminogen activator (SUPA) activates bovine, but not human, plasminogen. Activation of the plasminogen system causes degradation of the extracellular matrix and facilitates spreading of bacteria and invasive infection. This species specificity may partially explain the very limited incidence of human disease from this organism.

Scientific Evidence by Area of Use

Area 1: Oral Probiotic / Dental and Periodontal Health (Strain KJ2sm)

Background and Strain Isolation

S. uberis strain KJ2 was among the earliest reported Streptococcus strains displaying a probiotic benefit, isolated from the subgingival plaque of a healthy adult subject in 1985 (Hillman et al., 1985). This strain, designated KJ2sm (also written as KJ2), is taxonomically Streptococcus uberis but was isolated from a human oral cavity, distinguishing it from bovine mastitis strains. The two particular strains used in the ProBiora3 formulation, S. oralis KJ3sm and S. uberis KJ2sm, were isolated from the mouth of a human volunteer and have been extensively characterized.

Clinical Evidence: Pilot Human Trial

A pilot human clinical trial was conducted to assess the safety and to test the ability of a probiotic mouthwash (ProBiora3) to affect the levels of Streptococcus mutans and certain known periodontal pathogens in the mouth when administered twice daily over a period of 4 weeks. The mouthwash was tested at two dose levels: 10⁶ and 10⁸ colony forming units each of Strep. oralis strain KJ3sm, Strep. uberis strain KJ2sm, and the spontaneous lactic acid-deficient variant of Strep. rattus, strain JH145. Substantial decreases in the levels of the marker bacteria were observed. No safety issues were noted with the twice daily application of this mouthwash. Despite the small number of subjects and the use of young, orally healthy adults, along with the inherent variability in the microbiological measurements, the probiotic mouthwash was able to substantially affect the levels of dental pathogens in saliva and periodontal subgingival plaque.

Evidence strength: This pilot trial was preliminary in nature — small sample size, short duration (4 weeks), limited to young, orally healthy adults. The investigators themselves noted these as limitations. It should be characterized as hypothesis-generating evidence only.

Clinical Evidence: Randomized Controlled Trial in Periodontitis

A randomized controlled trial aimed to evaluate the adjunctive effects of a Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145 containing probiotic tablet after scaling and root planing (SRP). Forty-eight periodontitis patients were included in this double-blind, placebo-controlled clinical trial. After root planing, patients used either a placebo or a probiotic tablet twice a day for 12 weeks. The pocket probing depth (primary outcome measure), bleeding on probing and relative attachment levels were measured at baseline, 12 and 24 weeks. At baseline, 4, 8, 12 and 24 weeks, microbiological sampling was performed and plaque and gingival indices were recorded.

Evidence strength: This was a double-blind, placebo-controlled RCT with 48 subjects. While stronger in design than the pilot trial, the sample size was modest, the treatment involved a multi-strain formulation (making it impossible to attribute effects to S. uberis KJ2 alone), and the clinical outcomes specifically attributable to S. uberis strain KJ2sm cannot be isolated from those of the co-administered strains.

Mechanism of Action in Oral Health Context

Colonization of the tooth surface by probiotic Streptococcus strains such as S. oralis KJ3 and S. uberis KJ2 has been shown to shift the microbiome of the oral cavity to a healthier state (Zahradnik et al., 2009). The proposed mechanism is competitive exclusion combined with hydrogen peroxide production. The S. oralis strain and, to a lesser degree, the S. uberis strain produce hydrogen peroxide, and the mechanism of antagonistic activity against periodontal pathogens has been demonstrated to depend on this metabolic activity. It is notable from this source that S. uberis KJ2sm is a secondary contributor to H₂O₂ production compared to S. oralis KJ3sm, which is the dominant hydrogen peroxide producer in the formulation.

Area 2: Bovine Mastitis Pathogen Context (Veterinary Science)

The overwhelming body of published science on S. uberis concerns its role as a primary cause of intramammary infection (IMI) in dairy cattle. Bovine mastitis is an inflammation of the mammary gland which can result from invasion by pathogens including Streptococcus uberis. This pathogen is an environmental pathogen associated with subclinical and clinical intramammary infection (IMI) in both lactating and non-lactating cows, which can persist in the udder and cause a chronic infection in the mammary gland. Despite the important economic losses and increased prevalence caused by S. uberis mastitis, virulence factors involved in bacterial colonization of mammary glands and the pathogenic mechanisms are not yet clear.

S. uberis mastitis appears as up to 1 month of IMI duration (termed transient) and greater than 1 month (persistent), with persistence longer than 2 months termed chronic. Streptococcus uberis is a common environmental mastitis pathogen, but many molecular studies indicate contagious transmission.

Area 3: Saccharomyces cerevisiae Fermentation Product as Dietary Supplement against S. uberis Mastitis Challenge

One PMC-indexed study is relevant for noting how a dietary supplement (administered to dairy cattle) was evaluated against an experimental S. uberis challenge — though this is a veterinary, not a human, dietary supplement study. The study aimed to characterize the protective effects and molecular mechanisms of action of a Saccharomyces cerevisiae fermentation product (NTK) in response to a mastitis challenge. Eighteen mid-lactation multiparous Holstein cows (n = 9/group) were fed the control diet or the control diet supplemented with 19 g/d NTK for 45 days and then infected in the right rear quarter with 2,500 CFU of Streptococcus uberis. This study is included because it illustrates a paradigm in which S. uberis serves as a challenge agent to evaluate dietary supplement efficacy — the converse of S. uberis itself being the supplement.

Area 4: Herbal and Plant-Based Approaches to S. uberis Infection (Phytoceutical Research)

Several studies have investigated plant-derived preparations for their activity against S. uberis, primarily in the veterinary context. This research is not studying S. uberis as an ingredient; rather, it studies S. uberis as the target of antimicrobial phytochemicals. Studies have assessed the ability of herbal products (phytoceuticals) to eliminate experimentally induced Streptococcus uberis mastitis. These herbal products are used in organically managed dairy cattle to maintain or promote udder health. The products tested included an intramammary product, a topical product, and a product applied to the vulvar area. These products are not approved by the US FDA for treatment of mastitis but are sold to enhance milk quality or for maintenance or improvement of udder health.

Tanacetum vulgare L. flower and leaf acetonic and ethanolic extracts have demonstrated antibacterial action against clinical isolates that cause bovine mastitis, including Streptococcus uberis. These remain in vitro and animal-context findings with no established translation to human therapeutic applications.

Human Infections: Pathogenic Significance in Humans

Streptococcus uberis, the most frequent cause of mastitis in lactating cows, is considered essentially non-pathogenic for humans. Only a few case reports have described human infections with this microorganism, which is notoriously difficult to identify.

Recent case reports have documented its ability to cause opportunistic infections in humans, particularly in immunocompromised individuals, where it has been implicated in bacteremia, endocarditis, pneumonia, and urinary tract infections. The zoonotic potential of S. uberis has been suggested by multiple case reports, with documented infections in individuals with direct or indirect exposure to livestock and dairy products.

S. uberis has been reported as a cause of urinary tract infection. Gülen et al. described seven cases out of 148 culture-positive urinary tract infections from patients living in a rural Turkish region. The authors speculate that patients became infected through frequent contact with cows and milk. One other case of S. uberis urinary tract infection was described by Lazinska et al. in 47 urine samples from 42 renal transplant recipients. Unfortunately, clinical presentation, treatment and outcome in patients with S. uberis urinary tract infection have not been specified in detail.

One extensively documented human case involved a haemodialysis patient: a 75-year-old male haemodialysis patient developed a severe foot infection with osteomyelitis and bacteraemia. Both Streptococcus uberis and Staphylococcus aureus were identified in wound secretion and blood samples using mass spectrometry. The presence of S. uberis was confirmed by superoxide dismutase A sequencing. The patient recovered after amputation of the forefoot and antibiotic treatment with ampicillin/sulbactam. He had probably acquired the infection while walking barefoot on cattle pasture land. This is the first case report of a human infection with S. uberis confirmed by modern molecular technology.

A review of the medical literature showed that previously reported cases of S. uberis infections were based on biochemical identification, raising serious concern about the real occurrence of S. uberis in humans. Immunocompromised patients, particularly those with end-stage renal disease requiring hemodialysis, prolonged immunosuppressive therapy, or prosthetic valve replacements, are at heightened risk. These patients often exhibit impaired immune responses, making them more susceptible to infections by uncommon pathogens. Given the rarity of S. uberis in human disease, clinicians may overlook its clinical significance, leading to potential delays in diagnosis and treatment.

Body Systems and Health Areas Associated with S. uberis

• Oral cavity / periodontal system (probiotic strain KJ2sm): Streptococcus oralis (S. oralis KJ3), Streptococcus uberis (S. uberis KJ2), and Streptococcus rattus (S. rattus JH145) are naturally-occurring oral bacteria that can act as antagonists and may be welcome adjuncts in the efforts to reduce or replace harmful oral bacteria.
• Mammary gland (pathogen — bovine): Streptococcus uberis is established as an environmental pathogen causing bovine mastitis.
• Urinary tract (rare human infections): S. uberis has been reported as a cause of urinary tract infection in humans.
• Bloodstream and deep tissues (opportunistic human infections in immunocompromised hosts): Case reports document bacteremia, endocarditis, pneumonia, and urinary tract infections in immunocompromised individuals.
• Immune system (inflammasome — in bovine models): Research has shown activation of the NLRP3/caspase-1 inflammasome pathway and IL-1β production during S. uberis infection of bovine mammary macrophages, consistent with inflammasome activation.

Dosage Forms and Doses Reported in Studies

The following dosages are reported exclusively from cited human or preclinical studies and are not treatment recommendations.

Oral Probiotic Formulation (Strain KJ2sm in ProBiora3®)

• Pilot human clinical trial (mouthwash): The pilot human clinical trial tested the ability of a probiotic mouthwash (ProBiora3) to affect dental pathogen levels when administered twice daily over a period of 4 weeks. The mouthwash was tested at two dose levels: 10⁶ and 10⁸ colony forming units (CFU) each of Strep. oralis strain KJ3sm, Strep. uberis strain KJ2sm, and the spontaneous lactic acid-deficient variant of Strep. rattus, strain JH145.
• Subchronic toxicity (rat study): A blend of 3 natural strains — Streptococcus uberis KJ2, Streptococcus oralis KJ3, and Streptococcus rattus JH145 — was administered to rats orally once daily (5 days per week) at doses of 0, 10⁶, or 10⁹ colony-forming units of each strain for 14 weeks.
• RCT in periodontitis patients (tablet): In a double-blind, placebo-controlled clinical trial with 48 periodontitis patients, patients used either a placebo or a probiotic tablet twice a day for 12 weeks following root planing. The specific CFU dose per tablet is not reported in the available abstract.

Veterinary Supplement Study (Reference Only)

• Saccharomyces cerevisiae fermentation product (NTK) against S. uberis challenge in cattle: Cows were fed the control diet supplemented with 19 g/d NTK for 45 days prior to an experimental S. uberis challenge with 2,500 CFU.

Safety Considerations

Probiotic Strain KJ2sm: Preclinical Safety

A subchronic toxicity study investigated adverse effects, if any, of a blend of 3 natural strains including Streptococcus uberis KJ2. The blend was administered to rats orally once daily (5 days per week) at doses of 0, 10⁶, or 10⁹ colony-forming units of each strain for 14 weeks. The results, as well as a toxicity study conducted in rats, revealed no adverse effect of the probiotic mouthwash by daily usage, which on the other hand contributed to maintaining both dental and periodontal health.

A clinical study of Streptococcus oralis strain KJ3sm, Streptococcus uberis strain KJ2sm, and Streptococcus rattus strain JH145 as a mouthwash (ProBiora3™) was conducted by Zahradnik et al. The safety study proved the probiotic microorganisms did not alter the oral microbial flora.

Pathogenic Species Safety Concerns

It is critical to distinguish strain-specific safety from species-level risk. The species S. uberis as a whole carries documented, though rare, potential for opportunistic human infection. In vitro experiments demonstrated that S. uberis can readily develop penicillin resistance, and microbial analysis of bacterial populations in treated milk showed that S. uberis can grow even in cold storage.

Immunocompromised patients, particularly those with end-stage renal disease requiring hemodialysis, prolonged immunosuppressive therapy, or prosthetic valve replacements, are at heightened risk for opportunistic infections. These patients often exhibit impaired immune responses, making them more susceptible to infections by uncommon pathogens.

Antimicrobial Resistance Profile

Antimicrobial resistance in S. uberis is a documented and growing concern across multiple geographies. Streptococcus uberis isolates have shown high levels of resistance to tetracycline (59%), followed by streptomycin (38%) and clindamycin (29%). Although all of the isolates in a Czech study were susceptible to beta-lactams, a relatively high percentage of intermediately susceptible isolates was recorded for ampicillin (44%) and penicillin (18%).

The majority of S. uberis strains in a Thai study were resistant to tetracycline (187/228, or 82.02%), followed by ceftiofur (44/228, or 19.30%), and erythromycin (19/228, or 8.33%). The tetracycline resistance reported in Thailand is higher than that reported in other countries, such as China (59%), Germany (42.3%), Canada (38.6%), and Sweden (12%).

Several studies have reported the presence of various AMR genes, such as the lincomycin resistance gene (lnuD), erythromycin resistance gene (ermB), and macrolide resistance gene (mph(B)) in S. uberis.

Streptococcus uberis is a potential reservoir of antimicrobial resistance genes. The use of antimicrobials to treat bovine mastitis has reduced the susceptibility of this microorganism to several antibiotics, underscoring the importance of monitoring antimicrobial use in veterinary practice.

High susceptibility of S. uberis to penicillins has been confirmed in multiple studies, with beta-lactams currently serving as the first-line antimicrobials for S. uberis mastitis treatment.

Diagnostic Misidentification Risk

A review of the medical literature showed that previously reported cases of S. uberis infections were based on biochemical identification, raising serious concern about the real occurrence of S. uberis in humans. This is relevant from a safety and surveillance standpoint: the true incidence of human infection may be underestimated due to misidentification, or conversely, some reported cases may represent misclassified organisms.

Regulatory and Classification Status

Streptococcus uberis as a species does not appear on the EFSA Qualified Presumption of Safety (QPS) list, the WHO essential medicines list, ESCOP monographs, German Commission E monographs, or the US Pharmacopeia as an approved probiotic or dietary supplement ingredient. The specific strain KJ2sm, as formulated in ProBiora3®, has been marketed in the United States as an oral health supplement; however, no comprehensive regulatory approval as a probiotic of demonstrated efficacy in a recognized disease indication has been identified in searched peer-reviewed or regulatory sources.

In the veterinary sphere, there is no vaccine on the European market with the specific indication for bovine mastitis caused by S. uberis. A vaccine called "Streptococcus uberis Bacterin" (product code 2851.00) marketed by Hygieia Biological Laboratories (USA) exists on the US market under a conditional license; this vaccine is based on a classic bacterin obtained from inactivated cultures of S. uberis, and the definitive marketing authorization is pending until efficacy studies endorse the claims.

Summary of Evidence Quality

The scientific evidence for Streptococcus uberis as a beneficial dietary supplement or probiotic ingredient for human health is limited and must be assessed honestly:

• Oral health (strain KJ2sm, multi-strain formulations): There is a small number of clinical studies — one pilot trial and at least one RCT — of the multi-strain ProBiora3 formulation containing S. uberis KJ2sm. Both involved small populations, short durations, and multi-strain designs that prevent attribution of effects to S. uberis KJ2sm alone. Preliminary in vitro studies suggest that S. uberis strains may support immune modulation and gastrointestinal integrity, although these effects have not yet been robustly confirmed in large-scale human clinical trials. Overall evidence strength: preliminary; further well-powered, strain-specific RCTs are needed.
• Bovine mastitis pathogenesis: Extensive peer-reviewed literature supports S. uberis as a clinically significant veterinary pathogen. Evidence in this domain is strong and well-established, but it characterizes the organism as a disease agent rather than a beneficial ingredient.
• Human infections: Evidence is limited to case reports only. No epidemiological cohort or case-control studies have been conducted on human S. uberis infection. Evidence strength: very limited; chiefly anecdotal (individual case reports).
• Gastrointestinal health in humans: No peer-reviewed human clinical evidence was identified in the searched sources supporting the use of S. uberis specifically for gut health outcomes. Claims in this area cannot be supported by the scientific literature available.

References

• Eryildiz C, et al. (2017). A rarely isolated bacterium in microbiology laboratories: Streptococcus uberis. PubMed PMID 28566081.
• Aarestrup FM, et al. (2000). Evaluation of PCR Methods for Rapid Identification and Differentiation of Streptococcus uberis and Streptococcus parauberis. PMC87983.
• ScienceDirect Topics: Streptococcus uberis (Pharmacology/Toxicology overview).
• ScienceDirect Topics: Streptococcus uberis (Agricultural and Biological Sciences overview).
• USPTO Patent 10946085: Streptococcus uberis extract as an immunogenic agent.
• Schukken YH, et al. (2018). Effect of 3 phytoceutical products on elimination of bacteria in experimentally induced Streptococcus uberis clinical mastitis. Journal of Dairy Science.
• Springer: Sustainable management of bovine mastitis caused by major pathogens using medicinal plants: a review. Dairy Science and Management (2025).
• Vailati-Riboni M, et al. (2021). Feeding a Saccharomyces cerevisiae fermentation product improves udder health and immune response to a Streptococcus uberis mastitis challenge. PMC8028142.
• Hassan J, et al. (2023). Diversity of Streptococcus spp. and genomic characteristics of Streptococcus uberis isolated from clinical mastitis of cattle in Bangladesh. Frontiers in Veterinary Science.
• Prado ME, et al. (2015). Role of Streptococcus uberis adhesion molecule in the pathogenesis of Streptococcus uberis mastitis. PubMed PMID 26216456.
• Oliver SP, et al. (1998). Virulence Factors of Streptococcus uberis Isolated From Cows With Mastitis. Journal of Veterinary Medicine, Series B.
• Yılmaz Çolak Ç. (2024). In silico analysis of virulence factors of Streptococcus uberis for a chimeric vaccine design. In Silico Pharmacology.
• Fessia AS, Odierno LM. (2021). Potential factors involved in the early pathogenesis of Streptococcus uberis mastitis: a review. Folia Microbiologica.
• Genomic Characterization and Antimicrobial Resistance Profile of Streptococcus uberis Strains Isolated from Cows with Mastitis from Northwestern Spain. Antibiotics (2025).
• Tassi R, et al. (2021). A Paradox in Bacterial Pathogenesis: Activation of the Local Macrophage Inflammasome Is Required for Virulence of Streptococcus uberis. PMC7768481.
• Valentiny C, et al. (2015). Streptococcus uberis and Staphylococcus aureus forefoot and blood stream co-infection in a haemodialysis patient: a case report. BMC Nephrology. PMC4446856.
• Misidentification of Streptococcus uberis as a Human Pathogen: A Case Report and Literature Review. International Journal of Infectious Diseases (2015).
• Unusual Presentation of Streptococcus uberis Bacteremia in a Complex Patient: A Case Report. PMC12069958 (2025).
• Antimicrobial Resistance Profiles and Genes in Streptococcus uberis Associated With Bovine Mastitis in Thailand. PMC8416076 (2021).
• Zouharova M, et al. (2023). Antimicrobial Susceptibility and Resistance Genes in Streptococcus uberis Isolated from Bovine Mastitis in the Czech Republic. Antibiotics.
• Antimicrobial Susceptibility and Resistance Genes in Streptococcus uberis Isolated from Bovine Mastitis in the Czech Republic. PMC10604623.
• Sequence Types and Antimicrobial Resistance Profiles of Streptococcus uberis Isolated From Bovine Mastitis. Frontiers in Veterinary Science (2019).
• Application of MALDI-TOF MS to Identify and Detect Antimicrobial-Resistant Streptococcus uberis Associated with Bovine Mastitis. PMC11278855.
• Leigh SA, et al. (2009). Evidence for niche adaptation in the genome of the bovine pathogen Streptococcus uberis. BMC Genomics. PMC2657157.
• Zadoks RN, et al. (2005). Ribotyping of Streptococcus uberis from a dairy's environment, bovine feces and milk. Veterinary Microbiology.
• Whole-Genome Sequence Analysis of Antimicrobial Resistance Genes in Streptococcus uberis and Streptococcus dysgalactiae Isolates from Canadian Dairy Herds. PMC5438997.
• Zahradnik RT, et al. Preliminary assessment of safety and effectiveness in humans of ProBiora3, a probiotic mouthwash. ResearchGate.
• Hillman JD, et al. (2009). Safety Assessment of ProBiora3, a Probiotic Mouthwash: Subchronic Toxicity Study in Rats. International Journal of Toxicology.
• The effect of a streptococci containing probiotic in periodontal therapy: A randomized controlled trial. ResearchGate.
• Probiotics for oral health: a critical evaluation of bacterial strains. Frontiers in Microbiology / PMC11228166 (2024).
• Hillman JD, et al. Dental whitening effect of an oral probiotic. OA Text.
• ScienceDirect Topics: Streptococcus parauberis (overview including S. uberis ecology).
• Comparison of Virulence Patterns Between Streptococcus uberis Causing Transient and Persistent Intramammary Infection. Frontiers in Veterinary Science (2022).
• Virulence factors of bovine mastitis pathogens: distribution, pathogenesis, and emerging vaccines. PMC12892978.
• Sequence characterisation and novel insights into bovine mastitis-associated Streptococcus uberis in dairy herds. Scientific Reports (2021).
• ScienceInsights: What Is Streptococcus uberis and Where Is It Found? (2025).